다른 서비스와 비교했을 때 SLRX 의 PB 비율은 어느 정도인가요?

SLRX은 Price-To-Book 비율(0.7x)을 기준으로 볼 때 동종 업계 평균(1.6x)과 비교했을 때 좋은 가치를 가지고 있습니다.

SLRX 의 PB 비율은 US Biotechs 업계의 다른 회사와 어떻게 비교됩니까?

SLRX 은 Price-To-Book 0.7 US Biotechs 업계 평균( 1.9 x).

SLRX 의 PB 비율과 공정 PB 비율은 어떻게 되나요? 회사의 예상 수익 성장률, 이익 마진 및 기타 위험 요소를 고려한 예상 PB 비율입니다.

평가 분석을 위한 SLRX 의 Price-To-Book 공정 비율을 계산하기에는 데이터가 부족합니다.

미래 현금 흐름을 볼 때 SLRX 의 공정 가격은 얼마인가요? 이 추정에는 할인된 현금흐름 모델을 사용합니다.

평가 분석을 위해 SLRX 의 공정 가치를 계산하기에는 데이터가 부족합니다.

애널리스트의 12개월 전망은 무엇이며 컨센서스 목표가에 대한 통계적 신뢰도가 있나요?

가격 예측을 표시하기에는 데이터가 부족합니다.

Salarius Pharmaceuticals (Nasdaq:SLRX) - 주가, 뉴스 및 분석

SLRX 주식 개요

임상 단계의 생명공학 회사인 살라리우스 파마슈티컬스는 미충족 의료 수요가 있는 암 치료제를 개발하는 데 주력하고 있습니다. 자세한 내용

SLRX 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	0/6
과거 실적	0/6
재무 상태	3/6
배당금	0/6

위험 분석

지난 1년 동안 주주가 크게 희석되었습니다.

수익은 향후 3년간 연평균 63.9% 씩 감소할 것으로 예상됩니다.

의미 있는 시가총액이 없습니다. ( $2M )

수익이 1백만 달러 미만인 경우 ( $0 )

+ 3 더 많은 위험

Salarius Pharmaceuticals, Inc. 경쟁사

Coeptis Therapeutics Holdings

NasdaqCM:COEP

US$8.0m

Cyclerion Therapeutics

NasdaqCM:CYCN

US$3.6m

Edesa Biotech

NasdaqCM:EDSA

US$7.0m

Enzon Pharmaceuticals

OTCPK:ENZN

US$5.6m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Salarius Pharmaceuticals
과거 주가
현재 주가	US$1.37
52주 최고치	US$7.27
52주 최저치	US$1.26
베타	0.93
11개월 변경	-17.96%
3개월 변경 사항	-24.73%
1년 변경 사항	-74.05%
33년 변화	-99.01%
5년 변화	-99.83%
IPO 이후 변화	-99.94%

최근 뉴스 및 업데이트

Recent updates

Salarius pharmaceuticals announces 1-for-25 reverse stock split

Oct 14

Salarius adds 12% after updates on clinical programs and financials

Sep 13

Salarius Pharma adds two Mayo Clinic sites to phase 1/2 trial of Seclidemstat as treatment for cancers

Aug 22

Salarius Pharmaceuticals GAAP EPS of -$0.09 beats by $0.01

Aug 08

Salarius Pharmaceuticals and VolitionRx enter into R&D collaboration agreement

Aug 02

Salarius Pharma reports new seclidemstat results in Ewing sarcoma and other solid tumors at ASCO21

Jun 07

Salarius Pharmaceuticals (SLRX) Investor Presentation - Slideshow

May 27

Salarius Pharmaceuticals (NASDAQ:SLRX) Shareholders Have Enjoyed An Impressive 155% Share Price Gain

Feb 09

주주 수익률

	SLRX	US Biotechs	US 마켓
7D	2.2%	2.5%	2.2%
1Y	-74.1%	16.1%	31.6%

수익률 대 산업: SLRX 지난 1년 동안 16.1 %를 반환한 US Biotechs 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: SLRX 지난 1년 동안 31.6 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is SLRX's price volatile compared to industry and market?
SLRX volatility
SLRX Average Weekly Movement	12.3%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

안정적인 주가: SLRX 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: SLRX 의 주간 변동성은 지난 1년 동안 21% 에서 12% 로 감소했지만 여전히 US 주식의 75%보다 높습니다.

회사 소개

설립	직원	CEO	웹사이트
n/a	2	David Arthur	www.salariuspharma.com

살라리우스 파마슈티컬스는 임상 단계의 생명공학 회사로 의학적 미충족 수요가 있는 암 치료제를 개발하는 데 주력하고 있습니다. 주요 후보 물질은 진행성 고형 종양과 유잉 육종 치료를 위한 임상 1상/2상 시험 중인 저분자 억제제인 Seclidemstat(SP-2577)입니다. 또한 혈액암 및 고형 종양 치료를 위한 저분자 단백질 분해제인 SP-3164도 제공하고 있습니다.

Salarius Pharmaceuticals, Inc. 기본 사항 요약

Salarius Pharmaceuticals 의 수익과 매출은 시가총액과 어떻게 비교하나요?
SLRX 기본 통계
시가총액	US$1.97m
수익(TTM)	-US$4.99m
수익(TTM)	n/a

0.0x

P/S 비율

-0.4x

P/E 비율

SLRX 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
SLRX 손익 계산서(TTM)
수익	US$0
수익 비용	US$0
총 이익	US$0
기타 비용	US$4.99m
수익	-US$4.99m

최근 보고된 수익

Sep 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-3.47
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	11.2%

SLRX 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

SLRX 주식 개요

위험 분석

Salarius Pharmaceuticals, Inc. 경쟁사

NasdaqCM:COEP

US$8.0m

NasdaqCM:CYCN

US$3.6m

NasdaqCM:EDSA

US$7.0m

OTCPK:ENZN

US$5.6m

가격 내역 및 성능

최근 뉴스 및 업데이트

Salarius Pharmaceuticals, Inc., Annual General Meeting, Dec 20, 2024

Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with Mds and Cmml Presented At the 2024 European Hematology Association Annual Meeting

New major risk - Shareholder dilution

Nasdaq Grants an Additional 180-Day Grace Period to Salarius Pharmaceuticals to Regain Compliance

Salarius Pharmaceuticals, Inc. Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses

Salarius Pharmaceuticals, Inc. Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program

Recent updates

Salarius Pharmaceuticals, Inc., Annual General Meeting, Dec 20, 2024

Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with Mds and Cmml Presented At the 2024 European Hematology Association Annual Meeting

New major risk - Shareholder dilution

Nasdaq Grants an Additional 180-Day Grace Period to Salarius Pharmaceuticals to Regain Compliance

Salarius Pharmaceuticals, Inc. Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses

Salarius Pharmaceuticals, Inc. Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program

Salarius Pharmaceuticals Receives Notice from Nasdaq Stock Market

Insufficient new directors

Salarius Pharmaceuticals, Inc. FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients

Salarius Pharmaceuticals, Inc. announced that it has received $6.000001 million in funding

FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals' Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma

Salarius Pharmaceuticals Presents Sp-3164 Preclinical Data At the Inaugural Molecular Glue Drug Development Summit

Salarius Pharmaceuticals, Inc. to Present SP-3164 Targeted Protein Degrader Preclinical Data At the Inaugural Molecular Glue Drug Development Summit

Salarius Pharmaceuticals, Inc. Announces Investigators Present Clinical Data on Its Seclidemstat in Patients with MDS and CMML at the 2022 American Society of Hematology Annual Meeting

Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

Salarius Pharmaceuticals, Inc. Reports Impairment of Goodwill for the Three Months Ended September 30, 2022

Salarius Pharmaceuticals Presents Favorable Preclinical Data on Sp-3164 At the 5Th Annual Targeted Protein Degradation Conference

Salarius Pharmaceuticals, Inc. Announces Pause in New Patient Enrollment in its Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma and FET-Rearranged Sarcomas

Salarius pharmaceuticals announces 1-for-25 reverse stock split

Salarius adds 12% after updates on clinical programs and financials

Salarius Pharma adds two Mayo Clinic sites to phase 1/2 trial of Seclidemstat as treatment for cancers

Salarius Pharmaceuticals GAAP EPS of -$0.09 beats by $0.01

Salarius Pharmaceuticals, Inc. Adds Seattle Cancer Care Alliance and Oregon Health & Sciences as Clinical Sites for Ongoing Trial of Seclidemstat as A Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

Salarius Pharmaceuticals and VolitionRx enter into R&D collaboration agreement

Salarius Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 05, 2022

Salarius Pharmaceuticals Completes SP-3164 Pre-Investigational New Drug Meeting Process with the U.S. Food and Drug Administration

Salarius Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2022

Salarius Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Salarius Pharmaceuticals Appoints Daniela Santiesteban, Ph.D., to Director of Targeted Protein Degradation Program

Salarius Pharmaceuticals, Inc. (NasdaqCM:SLRX) acquired certain assets of DeuteRx, including DRX-164 for approximately $220 million.

Salarius Pharmaceuticals Achieves Dosing Milestone in Ongoing Phase 1/2 Sarcoma Trial

Consensus forecasts updated

Second quarter 2021 earnings released: US$0.069 loss per share (vs US$0.13 loss in 2Q 2020)

Salarius Pharmaceuticals Announces New Clinical Trial to Study Seclidemstat in Hematologic Cancers

Salarius Pharmaceuticals Presents New Research Data Demonstrating Seclidemstat’S Safety, Dosing, and Drug Activity At American Society of Clinical Oncology (Asco) 2021 Annual Meeting

Salarius Pharma reports new seclidemstat results in Ewing sarcoma and other solid tumors at ASCO21

Salarius Pharmaceuticals (SLRX) Investor Presentation - Slideshow

Price target decreased to US$4.10

Salarius Pharmaceuticals, Inc. Discloses Key Findings from Three Abstracts to be Presented at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

First quarter 2021 earnings released: US$0.061 loss per share (vs US$0.22 loss in 1Q 2020)

Full year 2020 earnings released: US$0.50 loss per share (vs US$2.12 loss in FY 2019)

Salarius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $19.999999 million.

Salarius Pharmaceuticals, Inc. Initiates Expansion Stage of Phase 1/2 Clinical Trial of Seclidemstat in Patients with Ewing Sarcoma and Ewing-Related Sarcomas

Salarius Pharmaceuticals, Inc. Completes Dose-Escalation Stage of Phase 1/2 Clinical Trial in Relapsed and Refractory Ewing Sarcoma Patients, Initiates Expansion Stage in Ewing and Ewing-Related Sarcoma Patients

Salarius Pharmaceuticals (NASDAQ:SLRX) Shareholders Have Enjoyed An Impressive 155% Share Price Gain

New 90-day high: US$1.58

Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

New 90-day high: US$1.35

Salarius Pharmaceuticals, Inc. Announces Developing Seclidemstat

Salarius Pharmaceuticals receives second installment of $1.7M in payments

Salarius Pharma raises $3.5M via warrant exercise

New 90-day high: US$1.08

Revenue beats expectations, earnings disappoint

Third quarter 2020 earnings released: US$0.096 loss per share

Salarius Pharmaceuticals EPS in-line, beats on revenue

New 90-day low: US$0.73

New 90-day low: US$0.80

New 90-day low - US$0.99

Earnings released

Salarius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $5.353451 million.